Celltrion to seek new drug, CDMO partners at int'l pharmaceutical exhibition in Milan
Celltrion will use one of the world's largest pharmaceutical trade shows next month to seek partners in new drug development, contract manufacturing and supply chains, the Korean biopharmaceutical company said Tuesday. The company will take part in CPHI Worldwide, which runs Oct. 6-8 in Milan. Now in its 37th year, the event covers pharmaceutical manufacturing, supply chains and contract…
Celltrion, a leading Korean biopharmaceutical company, will attend the CPHI Worldwide pharmaceutical trade show in Milan next month to seek partners for new drug development, contract manufacturing, and supply chains, according to a Tuesday announcement. The event, now in its 37th year, will take place from October 6-8 and is expected to attract over 60,000 industry professionals from around 2,400 companies in 170 countries.
Celltrion, known for developing biosimilars, will focus on partnerships in oncology, obesity and metabolic diseases, and autoimmune diseases for its new drug research. The company has recently begun seeing promising results in these areas, which has fueled its ambition to become a global developer of new drugs. As demand for its existing products increases, Celltrion also plans to strengthen its relationships with overseas raw material suppliers and contract manufacturers.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
